TG Therapeutics pulls BLA/sNDA for U2 in CLL and SLL and sale of Ukoniq

US biotech TG Therapeutics (Nasdaq: TGTX) saw its shares plunge almost 32% to $6.03, after it announced the voluntary withdrawal of the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA) for the combination of ublituximab and Ukoniq (umbralisib) - combination referred to as U2 - for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The decision to withdraw was based on recently updated overall survival (OS) data from the UNITY-CLL Phase III trial that showed an increasing imbalance in OS.

In addition, the company announced that it has voluntarily withdrawn Ukoniq from sale for the approved indications of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for the treatment of adult patients with follicular lymphoma (FL) who have received at least three prior systemic therapies. Ukoniq was granted accelerated approval in these indications by the Food and Drug Administration in February 2021. The company’s decision to withdraw Ukoniq from the market was primarily based on the withdrawal of the BLA and sNDA for U2 in CLL.

Michael Weiss, chairman and chief executive of TG Therapeutics stated: “We were very disappointed to see that the recently updated overall survival data showed an increasing survival imbalance in favor of the control arm. Accordingly, we and our advisors determined that we should withdraw the BLA/sNDA for U2 in CLL. Additionally, we made the difficult decision to withdraw Ukoniq from sale for the approved indications in MZL/FL.”